Tolerability of repetitive dihydroergotamine infusions paired with an adjustment in preventive treatment strategy in chronic headache disorders in children and youth [PDF]
The Journal of Headache and PainBackground In adults, intravenous (IV) dihydroergotamine (DHE) has been shown to be effective at improving medium term outcomes in patients with chronic headache disorders. The IV formulation is utilized given its superior bioavailability.
Sara Pavitt +8 more
doaj +4 more sources
Relationship of dihydroergotamine pharmacokinetics, clinical efficacy, and nausea-A narrative review. [PDF]
HeadacheAbstract Objective To assess the relationships between dihydroergotamine (DHE) pharmacokinetic (PK) parameters, clinical efficacy, and nausea incidence to determine a DHE PK profile that optimizes efficacy while minimizing adverse events (AEs), particularly nausea. Background Dihydroergotamine is a widely used option for the acute treatment of migraine.
Lipton RB, Kollins JA, Albrecht D.
europepmc +4 more sources
Study participant impression of use and satisfaction with STS101 (dihydroergotamine nasal powder): Results from the open‐label ASCEND acute migraine study [PDF]
Headache: The Journal of Head and Face Pain, EarlyView.Abstract Objective/Background This study was undertaken to assess participants' impression of use and satisfaction with STS101 in a long‐term, open‐label safety study. The ASCEND study assessed the safety and tolerability of STS101, an investigational drug–device combination of 5.2 mg dihydroergotamine in a single‐use nasal delivery device for the ...
Jessica Ailani +4 more
openalex +2 more sources
Identification of potential diagnostic targets and therapeutic strategies for anoikis-related biomarkers in lung squamous cell carcinoma using machine learning and computational virtual screening [PDF]
Frontiers in PharmacologyObjectiveLung squamous cell carcinoma (LUSC) is a common subtype of non-small cell lung cancer (NSCLC) characterized by high invasiveness, high metastatic potential, and drug resistance, resulting in poor patient prognosis.
Xin Zhang +7 more
doaj +2 more sources
New characterization of dihydroergotamine receptor pharmacology in the context of migraine: utilization of a β-arrestin recruitment assay [PDF]
Frontiers in Neurology, 2023 IntroductionDihydroergotamine mesylate (DHE) is an established effective acute therapy for migraine and is often characterized by its broad receptor pharmacology.
Lisa McConnachie +7 more
doaj +2 more sources
Drug Repurposing to Inhibit Histamine N-Methyl Transferase [PDF]
Molecules, 2023 Lower activity of the histaminergic system is associated with neurological disorders, including Alzheimer’s disease (AD). Thus, the enhancement of histaminergic neurotransmission by inhibition of histamine N-methyl transferase (HNMT), which degrades ...
Elvia Mera Jiménez +5 more
doaj +2 more sources
In silico drug repurposing for potential HPV-induced skin wart treatment − A comparative transcriptome analysis [PDF]
Journal of Genetic Engineering and BiotechnologyIntroduction: Warts are dermal disorders resulting from HPV infection and can be transmitted by direct contact. Existing treatment approaches, such as topical treatment with salicylate, have low efficiency and demonstrate side effects.
Navid Kashani +3 more
doaj +2 more sources
Prophylactic Management of Vestibular Migraine: A Systematic Review. [PDF]
Ann Clin Transl NeurolABSTRACT Background Vestibular migraine (VM) is a neurological disorder characterized by episodic vertigo in patients with migraine, contributing to substantial functional impairment. Although VM is relatively common, a consensus on effective prophylactic treatments is lacking.
Almohammed HA +11 more
europepmc +2 more sources
Dihydroergotamine inhibits the vasodepressor sensory CGRPergic outflow by prejunctional activation of α2-adrenoceptors and 5-HT1 receptors [PDF]
The Journal of Headache and Pain, 2018 Background Dihydroergotamine (DHE) is an antimigraine drug that produces cranial vasoconstriction and inhibits trigeminal CGRP release; furthermore, it inhibits the vasodepressor sensory CGRPergic outflow, but the receptors involved remain unknown ...
Abimael González-Hernández +4 more
doaj +2 more sources
Peripheral blood immune landscape and NXPE3 as a novel biomarker for hypertensive intracerebral hemorrhage risk prediction and targeted therapy [PDF]
ImetaWe employed bulk RNA‐seq and scRNA‐seq techniques to analyze the immune dysregulation in patients with intracerebral hemorrhage (ICH). The study revealed that excessive inflammatory responses, neutrophil activation, and T‐cell dysfunction are the main characteristics of ICH.
Zhang M +6 more
europepmc +2 more sources